James Mond
No más puestos en curso
Origen de la red de primer grado James Mond.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Biotechnology | 13 | |
Biosynexus, Inc.
 Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Biosynexus, Inc. develops and markets pharmaceutical products. The company is headquartered in Rockville, MD.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a James Mond a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | General Counsel | |
| IMMUNOGEN, INC. | Biotechnology | Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| MERCK KGAA | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Pharmaceuticals: Major | Director of Finance/CFO | |
| REVANCE THERAPEUTICS, INC. | Pharmaceuticals: Major | General Counsel | |
| AFFIMED N.V. | Biotechnology | Director/Board Member | |
| Stanford University | College/University | Undergraduate Degree Undergraduate Degree | |
| BIOTEST AG | Pharmaceuticals: Other | Chairman | |
Astra Merck, Inc.
 Astra Merck, Inc. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, Astra Merck, Inc. is a company that sells pharmaceutical products. The company is based in Orlando, FL. The company was founded by Myrtle S. Potter, Thomas A. McCourt. Astra Merck was acquired by Astra AB from Merck & Co., Inc. on July 12, 1998 for $4,400 million. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ATON | Pharmaceuticals: Major | Director/Board Member | |
| Arizona State University | College/University | Graduate Degree | |
| DePaul University | College/University | Undergraduate Degree | |
| Purdue University | College/University | Undergraduate Degree | |
| Ramapo College of New Jersey | College/University | Undergraduate Degree | |
| University of Western Ontario | College/University | Undergraduate Degree | |
| State University of New York at Albany | College/University | Undergraduate Degree Undergraduate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree | |
| University of Detroit Mercy | College/University | Graduate Degree | |
| University of Maryland | College/University | Undergraduate Degree Undergraduate Degree | |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
| Ruprecht-Karls-Universität Heidelberg | College/University | Undergraduate Degree | |
| Ludwig-Maximilians-Universität München | College/University | Undergraduate Degree | |
| Uniformed Services University of the Health Sciences | College/University | Corporate Officer/Principal | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chairman | |
| REDPOINT BIO CORPORATION | Food: Specialty/Candy | Director/Board Member | |
Sidney Kimmel Cancer Center
 Sidney Kimmel Cancer Center Medical/Nursing ServicesHealth Services Part of Sanford Burnham Prebys Medical Discovery Institute, Sidney Kimmel Cancer Center provides medical research services. The company is based in San Diego, CA. Sidney Kimmel Cancer Center was acquired by Sanford Burnham Prebys Medical Discovery Institute on June 23, 2009 for $25 million. | Medical/Nursing Services | Director of Finance/CFO | |
| COGNITION THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| Naval Medical Research Institute | Corporate Officer/Principal | ||
ADMA Plasma Biologics, Inc.
 ADMA Plasma Biologics, Inc. BiotechnologyHealth Technology ADMA Plasma Biologics, Inc. develops medicines for the treatment of infectious diseases. The company was founded in 2007 and is headquartered in Hackensack, NJ. | Biotechnology | Director/Board Member Director/Board Member | |
| Lake Forest Graduate School of Management | College/University | Masters Business Admin | |
| Albert Einstein College of Medicine, Inc. | College/University | Doctorate Degree | |
| ALPHA TEKNOVA, INC. | Pharmaceuticals: Major | Director/Board Member | |
Astra Zeneca Oy
 Astra Zeneca Oy Miscellaneous Commercial ServicesCommercial Services Astra Zeneca Oy engages in the development and manufacture of biopharmaceutical products. It specializes in clinical drug research in oncology, diabetes, and cardiovascular diseases. The company was founded on March 19, 1965 and is headquartered in Espoo, Finland. | Miscellaneous Commercial Services | Chief Executive Officer | |
| National Center for Health Statistics | General Government | Corporate Officer/Principal | |
| The University of Chicago Booth School of Business | College/University | Masters Business Admin | |
Opertech Bio, Inc.
 Opertech Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Opertech Bio, Inc. provides taste testing solutions for food, beverage, flavor ingredients, pet food, and pharmaceutical industries. Its technology can be used to discover new flavor ingredients, measure palatability, and optimize flavor formulations. The firm has developed taste evaluation technology called Microtiter Operant Gustometer, or MOG, an automated high throughput system for rapid characterization of taste sensory properties. The company was founded by Scott M. Horvitz and R. Kyle Palmer and is headquartered in Philadelphia, PA. | Miscellaneous Commercial Services | Chairman | |
| University of Maryland School of Pharmacy | College/University | Doctorate Degree | |
| EQUILLIUM, INC. | Biotechnology | Director/Board Member | |
| NEUBASE THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Miscellaneous Commercial Services | Director/Board Member | |
| GAIN THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Neovii Biotech GmbH
 Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Biotechnology | Chief Executive Officer |
Estadísticas
Internacional
| Estados Unidos | 39 |
| Alemania | 8 |
| Reino Unido | 2 |
| Francia | 2 |
| Canadá | 2 |
Sectorial
| Health Technology | 25 |
| Consumer Services | 18 |
| Commercial Services | 4 |
| Health Services | 3 |
| Consumer Non-Durables | 2 |
Operativa
| Director/Board Member | 55 |
| Corporate Officer/Principal | 27 |
| Independent Dir/Board Member | 21 |
| Undergraduate Degree | 17 |
| Chief Executive Officer | 11 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Dov Goldstein | 28 |
| Eric Richman | 21 |
| Bernhard R. M. Ehmer | 16 |
| Irwin Scher | 14 |
| Martha Demski | 13 |
| Lawrence Guiheen | 10 |
| Helen Thackray | 8 |
| Marc S. Gelberg | 7 |
| Mathew Peters | 5 |
| Adam Pinkert | 4 |
| James Hauert | 3 |
| Doris Connell | 3 |
| Michael Goldstein | 3 |
| Theresa Gwaltney | 2 |
| Drew Pantello | 2 |
- Bolsa de valores
- Insiders
- James Mond
- Conexiones Empresas
